Huashan Hospital
Jim ing Zhang
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
COVID-19
Paxlovid
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 2000 participants |
| Official Title : | A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19 |
| Actual Study Start Date : | 2022-03-21 |
| Estimated Primary Completion Date : | 2023-03-30 |
| Estimated Study Completion Date : | 2027-03-30 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 12 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Huashan Hospital Affiliated to Fudan University
Shanghai, China,